Additionally, researchers have investigated the resistance mechanism of bevacizumab in the treatment of glioblastoma (GBM) and found that GBM cells secrete two cytokines, IL-8 and CCL2, which stimulate TAMs to produce TNFα, which activates endothelial cells (ECs). The gene discussed is CCL2; the disease is glioblastoma.